How TFPI isoforms affect blood clotting and bleeding disorders
Official title: Pre-mRNA Processing and Function of Alternatively Spliced Isoforms of TFPI
Funded at Oakland University · NIH-11393367 · Data updated 2026-11-12
A research project looks at how different forms of a natural anticoagulant (TFPI) in adults influence bleeding and clotting, especially in conditions like Factor V Leiden.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oakland University NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 11, 2025 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $248,954 |
| NIH project number | 5R00HL163412-04 |
| Project ID | NIH-11393367 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 years and older with or at risk for clotting disorders may be eligible for related future studies involving TFPI isoforms.
✕Less likely to help
If a patient does not have coagulation disorders related to TFPI, they may not experience direct benefits from this basic research.
What this research studies
This project studies how alternative splicing creates different TFPI protein variants in adults and how these variants behave in normal and disease-prone blood clotting. Researchers will examine how isoforms are produced at the RNA level and how they function to inhibit key clotting factors in real-life blood samples. The goal is to map which TFPI isoforms are present in specific tissues and circumstances, including embryonic development contexts and prothrombotic states. The findings could point to new ways to balance bleeding risk and clot formation in patients with coagulation disorders.
Why it matters
Potential benefit: If successful, the work could lead to better understanding of bleeding and clotting balance and inform future therapies to prevent clots or excessive bleeding.
How similar studies have gone: Previous research shows that TFPI and its isoforms influence coagulation, but the specific roles of each isoform in humans require more study.
Where this research is happening
-
Oakland University
Rochester, United States Active
Researchers
- Principal investigator: Siebert-Mckenzie, Amy — Oakland University
- Study coordinator: Siebert-Mckenzie, Amy
Related research
Other NIH-funded projects on the same topics.
-
Phospho-Regulation of Centrosome Assembly in C. elegans
A scientist-led study in a model worm investigates how chemical signals control how cells duplicate their organizing centers, which is important for healthy development and may relate to cancer when it goes wrong.
-
Small molecule activators of Neurolysin to help stroke recovery
Researchers are developing drug-like molecules that boost the brain’s natural protective enzyme, aiming to improve recovery after a stroke.
-
Understanding why prematurity affects vision and how to prevent it
Aims to understand how early eye development goes wrong in premature babies to prevent vision problems and nearsightedness.
-
Turning on a brain enzyme to help recovery after stroke
This project aims to develop pill-like drugs that switch on a brain enzyme called neurolysin to help protect and repair the brain after a stroke.
-
BMP2/ALK Signaling in Diabetic Retinopathy and Potential Therapies
This grant looks at how a specific signaling system in the eye may drive vision problems in diabetes and explores ways to block it to protect sight.
-
Understanding Spinocerebellar Ataxia Type 5
This research explores how changes in a specific gene lead to spinocerebellar ataxia type 5 (SCA5) and damage brain cells, aiming to find new ways to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.